OCT 31, 2024 8:00 AM PDT

Accelerate test internalization with PGDx elio™ plasma focus Dx, an FDA-authorized liquid biopsy-based genomic profiling solution

Sponsored by: Labcorp
Speaker

Event Date & Time
Date: October 31, 2024
Time: 8:00 AM (PST), 11:00 AM (EST), 4:00 PM (CET)
Abstract
Liquid biopsy next-generation sequencing (NGS) assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable or during disease progression. Extensive analytical validation of the targeted 33-gene assay, PGDx elio plasma focus Dx, has shown that detection of cancer-associated variants in circulating tumor DNA (ctDNA) is highly specific, sensitive, reproducible and accurate. Distribution of this kitted assay, including automated machine-learning software to generate reports, can inform precision oncology decision-making.
 
Learning Objectives
  • Use of comprehensive genomic profiling (CGP) and liquid biopsies in clinical workflows for cancer patients
  • Specifications and workflow of the PGDx elio plasma focus Dx assay
  • Validation efforts for FDA authorization of PGDx elio plasma focus Dx
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
 

You May Also Like
Loading Comments...
Event Countdown
  • 0 Days
  • 0 Hours
  • 0 Minutes
  • 0 Seconds